

# **BRAIN VOLUME CHANGES AS PREDICTORS OF FXTAS PROGRESSION**

*PERUBAHAN VOLUME OTAK SEBAGAI PREDIKTOR  
PERKEMBANGAN FXTAS*



**UCDAVIS**  
MLND INSTITUTE

**Thesis**

**Submitted to fulfill the assignment and fit-out requisite  
in passing Post-graduate Program Majoring Genetics Counseling  
Diponegoro University Semarang**

**Zukhrofi Muzar  
22010111400105**

**Biomedical Science Post Graduate Program  
Majoring Genetics Counseling  
Diponegoro University Semarang  
2014**

**THESIS**

**Brain volume changes as predictors of FXTAS progression**

**Arranged by**

**Zukhrofi Muzar**

**22010111400105**

Has been defended in front of the defense committee and has been approved by:

**UC Davis MIND Institute, USA**  
**Principal supervisor**

**Diponegoro University, Indonesia**  
**Principal Supervisor,**

Prof. Randi Hagerman, M.D.

DR. Dr. Tri Indah Winarni, M.Si.Med, PA  
NIP. 19630128 198902 2 001

**Supervisor,**

**Supervisor,**

Andrea Schneider, Ph.D.

Prof. Dr. Sultana MH Faradz, Ph.D.  
NIP. 19520202 197901 2 001

Recognition,  
Director of Graduate Programs  
Masters in Biomedical Sciences, Diponegoro University

Prof. Dr. dr. Tri Nur Kristina, DMM, M.Kes  
NIP. 195905271986032001

## **DECLARATION**

I hereby declare that this submission is my own work and that, to the best of my knowledge and belief, it contains no material previously published or written by another person nor material which to a substantial extent has been accepted for the award of any other degree or diploma of the university or other institute of higher learning, and there is no plagiarism as defined by Permendiknas No. 17, 2010. Knowledge obtained by the product of publishing or those not or not yet published, the sources were explained in the writing and reference.

Semarang, February 2014

Zukhrofi Muzar

## CURRICULUM VITAE

**Name** Zukhrofi Muzar

**Date of birth** 06-28-1986

**Place of Birth** Duri, Riau Province, Indonesia

**Email** [muzar.zukhrofi@gmail.com](mailto:muzar.zukhrofi@gmail.com)

**Institution Affiliation** City Health Office, Solok, West Sumatera Province, Indonesia

**Current address** Jalan lumba-lumba 130 Duri, Riau province, Indonesia 28884

**Nationality** Indonesian

**Education and Training**

**Nov 2012 – Nov 2013** Research fellow in neurodevelopmental disorders including fragile X syndrome and autism at UC Davis MIND Institute as part of master program in Biomedical Science, Diponegoro University, Indonesia

**2011-present** Master's Candidate in Biomedical Science, major: Genetic Counseling at Diponegoro University, Indonesia

**2008-2010** Medical Doctor, University of North Sumatera (USU), Indonesia

**2004-2008** Bachelor of Medicine, University of North Sumatera (USU), Indonesia

**Working Experience**

**2011 – present** General Practitioner (Civil servant) at Public Health Center, Tanjung Paku , Kota Solok, West Sumatera Province, Indonesia

**2010 – 2011** General practitioner at Emergency Unit Helvetia General Hospital, Medan, Indonesia  
General Practitioner at Athika Shiddiq Clinics, Medan, Indonesia  
Lecturer at Midwifery School Helvetia, Medan, Indonesia  
General Practitioner at Sumatera Clinics, Binjai, Indonesia

General Practitioner at Budi Medical Centre, Jati  
Jajar, Depok, Indonesia

### **Publications**

1. **Muzar Z**, Pasha M. The effect of the propolis on the growth of staphylococcus aureus. Abstract: 2<sup>nd</sup> Annual meeting of pharmacy, pharmacology and medicine, Medan, Indonesia, 2007
2. **Muzar, Z.**, Schneider, A., Adams, P., Hagerman, R. Narcotic use in FXTAS. Abstract: 1st international conference on the *FMRI* premutation, Italy, 2013.
3. Schneider, A., **Muzar, Z.**, Summers, S., Tassone, F., Seritan, A., Rivera, S., Grigsby, J., Hessler, D., Hagerman, P., Hagerman, R. Female characteristics of fragile X-associated tremor/ataxia syndrome. Abstract: 1st international conference on the *FMRI* premutation, Italy, 2013.
4. Lechpammer, M., Clegg, MS., **Muzar, Z.**, Huebner, PA., Jin, LW., Gospe, SM Jr. Pathology of Inherited Manganese Transporter Deficiency (Annals of Neurology, 2014)

### **Training / Workshop**

1. Animal Care and Use 101 at UC Davis, USA 2013
2. Use of Controlled Substances at UC Davis, USA 2013
3. Biological safety and medical waste management at UC Davis, USA 2013
4. Collaborative Institutional Training Initiative at UC Davis, USA 2013
5. 10<sup>th</sup> Medical Genetic Course: from basic to clinic. Faculty of Medicine Diponegoro University in collaboration with Department of Human Genetics, Radboud University Nijmegen Medical Centre, The Netherlands. Semarang, Indonesia, 2012
6. Workshop on Neurogenetics. Faculty of Medicine Diponegoro University. Semarang, Indonesia, 2012
7. National training on HIV AIDS. The Indonesian Doctor Association, Medan, Indonesia, 2010
8. Airway Management Workshop. 9<sup>th</sup> National Congress of Indonesia Society of Anesthesiologists, Medan, Indonesia, 2010
9. One Asia Forum. Asean foundation, Kuala Lumpur, Malaysia, 2009
10. Workshop on Youth and Multiculturalism, SEAMEO-SPAFA, Chiang Mai, Thailand, 2008
11. International Training on Disaster Management, World Youth Foundation, Melaka Malaysia, 2008
12. International Workshop Research Exchange, International Federation of Medical Students' Association (IFMSA), Osaka, Japan, 2007
13. PCR and DNA Sequencing. Rajawali Hospital, Bandung, Indonesia, 2006

## ACKNOWLEDGMENTS

I am extremely grateful to my supervisor, Professor Dr. Sultana MH Faradz, Ph.D., the head of CEBIOR-UNDIP, without her excellent support, guidance and patience, this thesis would not have been possible. She has provided me a great opportunity to work under her international networks at University of California Davis MIND Institute.

I would like to express my deepest gratitude to Professor Randi Hagerman, M.D., for his superb mentorship during my one-year internship at UC Davis MIND Institute. The valuable discussions and tremendous support from her are paramount in my life and development as an individual and as a professional. Her warm and positive attitude has given me example as a humanist physician-scientist.

I would really like to thank Andrea Schneider, Ph.D, assistance researcher at UC Davis MIND Institute for her engagement as co-supervisor in this master thesis. She has been giving me guidance in learning scientific writing and statistics. She has been very kind and supportive to be and was always prompt when I need help. I am amazed with her great scientific work and humble personality.

I would also like to thank Jun Yi Wang, Ph.D, postdoctoral fellow at UC Davis Mind and Brain, who helped me work on the brain MRI analysis at Susan Rivera's neuroimaging lab. She also taught me to analyze the brain MRI, as well as helped with arranging my research ideas and guided me through the application of various statistical techniques to my work.

Special thank goes to my principal supervisor, DR. Dr. Tri Indah Winarni, for the motivation, helping me build my self-confidence in this scientific world. She really helped me to simplify and to organize my ideas in this paper.

I would thank Prof. Dr. dr. Tri Nur Kristina, DMM, M.Kes and dr. Dodik Tugaworo, Sp.S (K) for critically examining my thesis.

I would also like to acknowledge the help of Patrick Adams, who provided me Brain MRI images and helped me to decide subjects for the study. Also special thanks to Kylee Cook who really helped with collecting molecular data.

I am most grateful to my friends Zach, Russell, and Arthur for providing me the favor to proofread this manuscript, covering my flaws in English writing.

I want to thank the Bureau of Planning and Overseas Coordination (BPKLN), Ministry of Education, Indonesia, especially to DR. AB Susanto, Msc as the excellent scholarship coordinator, for providing me with financial support during my study years.

I would also like to thank an awesome psychologist from Barcelona, Marieta Diez Juan, M.A., and her husband Angel, a young talented geneticist Dr. Reymundo Lozano, the best genetic counselor I have ever known Louise Gane, M.S., a brilliant autism researcher Tasha Oswald, Ph.D., for their friendship that helped me through some problems that I had been going through. They really provided some much needed humor and entertainment, cheering me up and stood by me through the good times and bad.

I would like to thank Julie, Jacky, Jonathan, Tasleem, in the Fragile X team at UC Davis MIND Institute who helped me with many things until small important technical problems.

I would also thank Dr. Tanjung, for her generous help with my data collection and let me borrow her flash drive for a month.

I would also like to thank all the staff of the Center for Biomedical Research (CEBIOR), Semarang, Central Java, Indonesia, Ardina Aprilani, Dwi Kustiani, Intus, Lusi Suwarsi, Rita Indriati, and Wiwik Lestari for their assistance during my study.

I thank to all of my colleagues at my master program, Bang Doni, Ira, Tami, Tya, Sari, Gara, Hesty, Mba Isna, Venty, Mba Ziske for their motivation, progress, and friendship.

Last, but by no means least, I would like to thank my parents, Ali Muzar and Murniati and my whole extended family. Being far away for two years from their youngest kid has been tough for us. I also want to thank my brother Zuharmen Muzar and my five sisters Zartina Muzar, Zuryetti Muzar, Zulia Muzar, Zullaili Muzar, Zahraini Muzar for helping me to get things done. Also, I thank them for helping me stay connected with my 12 amazing nephews and nieces who always bring me happiness.



## CONTENTS

<b>TITLE</b> .....	i
<b>APPROVAL SHEET</b> .....	ii
<b>DECLARATION</b> .....	iii
<b>CURRICULUM VITAE</b> .....	iv
<b>ACKNOWLEDGEMENTS</b> .....	vi
<b>CONTENTS</b> .....	ix
<b>LIST OF ABBREVIATIONS</b> .....	xi
<b>GLOSSARY</b> .....	xii
<b>LIST OF PANEL AND TABLES</b> .....	xiii
<b>LIST OF FIGURES</b> .....	xiv
<b>LIST OF APPENDICES</b> .....	xv
<b>ABSTRACT (ENGLISH)</b> .....	xvi
<b>ABSTRAK (INDONESIAN)</b> .....	xvii
<b>CHAPTER 1 INTRODUCTION</b> .....	<b>1</b>
1.1 Background.....	1
1.2 Research questions.....	3
1.3 Study objectives .....	3
1.3.1 General objective.....	3
1.3.2 Specific objectives.....	4
1.4 Research benefits.....	4
1.5 Originality.....	5
<b>CHAPTER 2 LITERATURE REVIEW</b> .....	<b>6</b>
2.1 Prevalence of FXTAS.....	6
2.2 Clinical phenotype of FXTAS.....	6
2.2.1 Spectrum of FXTAS symptoms .....	6
2.2.2 The role of gender in FXTAS.....	8
2.3 Diagnosis and clinical severity stage of FXTAS.....	10
2.4 Radiological findings in FXTAS.....	11
2.5 Neuropathological hallmark of FXTAS.....	13

2.6 Molecular mechanism of FXTAS.....	15
2.6.1 Triggering events.....	16
2.6.2 Features of cellular dysregulation.....	17
2.6.3 Additional factors leading to neurodegeneration and FXTAS.....	18
2.7 Quantitative brain measurement with FSL (Functional MRI of the- Brain software library)-SIENAX.....	19
2.8 Theoretical framework.....	22
2.9 Conceptual framework.....	22
<b>CHAPTER 3 RESEARCH METHODS.....</b>	<b>23</b>
3.1 Research field.....	23
3.2 Setting, Location and Period of Research.....	23
3.3 Research Design.....	23
3.4 Research subjects.....	23
3.5 Inclusion criteria.....	24
3.6 Exclusion criteria.....	24
3.7. Research variables.....	24
3.8 Molecular measures and clinical stage.....	25
3.9 Imaging data acquisition .....	28
3.10 Image processing.....	29
3.11 Operational definitions.....	30
3.12 Research flow.....	31
3.13 Statistical analysis.....	31
3.14 Research ethics.....	32
<b>CHAPTER 4 RESULTS.....</b>	<b>33</b>
<b>CHAPTER 5 DISCUSSION.....</b>	<b>38</b>
<b>CHAPTER 6 CONCLUSION AND FUTURE DIRECTION.....</b>	<b>41</b>
<b>CHAPTER 7 SUMMARY.....</b>	<b>43</b>
<b>RINGKASAN (INDONESIAN).....</b>	<b>45</b>
<b>REFERENCES .....</b>	<b>47</b>
<b>APPENDICES .....</b>	<b>58</b>

## LIST OF ABBREVIATIONS

BET	Brain extraction tool
CCP	Corpus callosum splenium
CNS	Central nervous system
CSF	Cerebrospinal fluid
DTI	Diffusion tensor imaging
FAST	FMRIB's automated segmentation tool
FLAIR	Fluid attenuated inversion recovery
FLIRT	FMRIB's linear image registration tool
<i>FMRI</i>	Fragile X mental retardation 1
FMRIB	Functional magnetic resonance imaging of the brain
FMRP	Fragile X mental retardation protein
FSL	FMRIB's software library
FSL	FMRIB software library
FXTAS	Fragile X associated tremor/ataxia syndrome
GMV	Grey matter volume (total)
HC	Healthy Control
MCP	Middle cerebellar peduncles
MNI152	Montreal Neurological Institute 152
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
PGMV	Peripheral grey matter volume (cortical)
PolyQ	Polyglutamine
RNA-BP	RNA binding protein
SD	Standard Deviation
SIENA	Structural image evaluation, using normalization, of atrophy
UTR	Untranslated region
VCSFV	Ventricular cerebrospinal fluid
WBV	Whole brain volume
WMH	White matter hyperintensities
WMV	White matter volume

## GLOSSARY

1. FXTAS Fragile X-associated tremor/ataxia syndrome (FXTAS); a neurodegenerative disorder associated with the premutation in the *FMRI* gene
2. Fragile X premutation CGG repeat length of 55 to 200 in the *FMRI* gene
3. Grey matter A major component of the central nervous system, consisting of neuronal cell bodies, neuropil (dendrites and myelinated as well as unmyelinated axons), glial cells (astroglia and oligodendrocytes) and capillaries; total grey matter in the brain
4. Head coil A special device that is placed around the person's head to help produce very detailed pictures of the brain
5. Peripheral grey matter Grey matter in cortex
6. SIENAX A package for estimation of whole brain volume (WBV), white matter volume (WMV), peripheral grey matter volume (PGMV), grey matter volume (GMV), and ventricular cerebrospinal fluid volume (VCSFV), normalized for subject head size
7. Ventricular Cerebrospinal fluid Cerebrospinal fluid in the ventricles of the brain
8. White matter Nerve fibers in the brain consists mostly of glial cells and myelinated axons that transmit signals from one region of the cerebrum to another and between the cerebrum and lower brain centers
9. Whole brain Total brain tissue

## LIST OF PANEL AND TABLES

<b>Panel</b>	Established and expanded features of FXTAS.....	8
<b>Table 1</b>	List of previous study.....	5
<b>Table 2</b>	Current diagnostic criteria of FXTAS.....	10
<b>Table 3</b>	FXTAS stage.....	28
<b>Table 4</b>	Characteristics of 45 research participants.....	33
<b>Table 5</b>	Annualized brain volume changes in two groups of FXTAS.....	34
<b>Table 6</b>	Comparisons of normalized brain volumes between patients with FXTAS at follow-up measurement and healthy controls using a 32-channel head coil.....	36
<b>Table 7</b>	Time-related brain volume changes of 21 patients with FXTAS.....	36

## LIST OF FIGURES

<b>Figure 1</b> The imaging features of FXTAS .....	12
<b>Figure 2</b> Neuronal intranuclear inclusions .....	14
<b>Figure 3</b> Proposed model for molecular neuropathology in fragile X- associated tremor/ataxia syndrome.....	16
<b>Figure 4</b> Schematic representation of the progression of CNS dysfunction...	19
<b>Figure 5</b> Example output from the FSL SIENAX tool.....	21
<b>Figure 6</b> Comparison of SIENAX output of patient with FXTAS and healthy control in axial view.....	35

## LIST OF APPENDICES

<b>Appendix I</b> Brain volume measurements at 2 time points of 21 patients with FXTAS.....	58
<b>Appendix II</b> SIENAX usage .....	59
<b>Appendix III</b> MRI 8 channel head coil protocol.....	62
<b>Appendix IV</b> MRI 32 channel head coil protocol.....	63
<b>Appendix V</b> Molecular data of 21 patients with FXTAS.....	64
<b>Appendix VI</b> Ethical clearance.....	65
<b>Appendix VII</b> Article.....	69

## ABSTRACT

**Background:** Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder that has a pathological effect on the brain. Hypothesis of the study is that the neuronal dysregulation leading to neuronal loss and white matter hyperintensity (WMH) in FXTAS may cause brain volume changes, and may be used as a measure of disease progression in FXTAS.

**Methods:** Brain volume changes in FXTAS were analyzed longitudinally on two separate time points using SIENAX (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/SIENA>). This study included 21 patients with FXTAS (mean age: 67.1y; SD = 6.2; 15 males and 6 females) with two MRI scans following initial diagnosis of FXTAS. The average interval between measurements was 2.2 years (SD = 1.2) with an interval range of 0.7-5 years. The patients were ascertained from families with and without a fragile X syndrome proband at the University of California at Davis Medical Center. Healthy control subjects (mean age: 70.9y SD = 6.7; 15 males and 9 females) were matched by age and gender to patients with FXTAS at their time 2 measurements, but the controls were assessed only once.

**Results:** Both annualized WBV and VCSFV change are predictors of occurrence of higher FXTAS stage. PGMV, GMV, WBV and VCSFV in the FXTAS subjects at time 2 were statistically different from healthy controls. The mean rates of WBV and VCSFV change in individuals with FXTAS were -1.5%/year and 3.05%/year respectively. There were no correlations of annualized VCSFV change and WBV change with both *FMRI* CGG repeat size and *FMRI* mRNA levels.

**Conclusion:** The results of our study revealed the importance of WBV and VCSFV measurements in the progression of FXTAS. Further study is needed to evaluate the rate of brain volume change with age in FXTAS and to investigate its benefit for making prognoses, monitoring disease progression, and determining the effectiveness of therapeutic treatment of FXTAS.

Keywords: FXTAS, fragile X premutation, longitudinal MRI, brain volume, White Matter Volume, Grey Matter Volume, Ventricular Cerebrospinal Fluid Volume



## ABSTRAK

**Latar belakang:** *Fragile X-associated tremor/ataxia syndrome* (FXTAS) adalah penyakit neurodegeneratif dengan efek patologis pada otak. Hipotesis dari studi ini adalah disregulasi saraf yang menyebabkan hilangnya neuron dan bertambahnya hiperintensitas *white matter* di FXTAS dapat menyebabkan perubahan volume otak, sehingga mungkin dapat digunakan sebagai ukuran perkembangan penyakit pada FXTAS.

**Metode:** Perubahan volume otak pada FXTAS dianalisis secara longitudinal pada dua titik waktu yang terpisah dengan menggunakan SIENAX (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/SIENA>). Penelitian ini melibatkan 21 pasien dengan FXTAS (rerata usia: 67,1 tahun SD = 6.2; 15 laki-laki dan 6 perempuan) yang memiliki 2 MRI otak setelah diagnosis FXTAS. Rerata interval antara pengukuran adalah 2,2 tahun (SD = 1.2) dengan *range* 0,7-5 tahun. Pasien diambil dari keluarga dengan dan tanpa *fragile X syndrome* di *University of California Davis Medical Center*. Subyek kontrol sehat (rerata umur: 70,9 tahun; SD = 6.7; 15 laki-laki dan 9 perempuan) dicocokkan sesuai dengan usia, jenis kelamin dengan subjek FXTAS pada pengukuran kedua, tetapi kontrol hanya dievaluasi satu kali.

**Hasil:** Perubahan WBV dan VCSFV tahunan adalah prediktor kejadian FXTAS stadium tinggi. PGMV, GMV, WBV dan VCSFV pada subjek FXTAS waktu ke dua berbeda signifikan secara statistik dibandingkan subjek kontrol. Rerata perubahan WBV dan VCSFV pada FXTAS masing masing adalah -1.5%/tahun dan 3.05%/tahun. Tidak ada hubungan antara perubahan WBV dan VCSFV dengan *FMRI CGG repeats* dan *FMRI mRNA*.

**Kesimpulan:** Penelitian ini membuktikan pentingnya pengukuran WBV dan VCSFV dalam perkembangan penyakit FXTAS. Penelitian lanjutan dibutuhkan untuk mengevaluasi tingkat perubahan volume otak sesuai dengan bertambahnya umur pada FXTAS dan untuk menginvestigasi keuntungannya dalam membuat prognosis, pengawasan perkembangan penyakit, dan menentukan terapi efektif untuk FXTAS.

*Keywords:* FXTAS, *fragile X premutation*, *longitudinal MRI*, *brain volume*, *White Matter Volume*, *Grey Matter Volume*, *Ventricular Cerebrospinal Fluid Volume*